Immunotherapy in Prostate Cancer

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

2016 • 29,943 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

2010 • 5,069 citations

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

2002 • 4,625 citations

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

2013 • 3,290 citations

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

2001 • 2,746 citations

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

2009 • 1,604 citations

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

2014 • 1,382 citations

Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

2006 • 1,069 citations

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

2010 • 947 citations

Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

2009 • 791 citations

The New B7s: Playing a Pivotal Role in Tumor Immunity

2007 • 188 citations

Lymphoproliferative Disorder in CTLA-4 Knockout Mice Is Characterized by CD28-Regulated Activation of Th2 Responses

1999 • 182 citations

Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 ⁺ T Lymphocytes

2008 • 94 citations

BTLA: a new inhibitory receptor with a B7-like ligand

2003 • 89 citations

Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer.

2010 • 12 citations